参考文献/References:
1 Riva P,Franceschi G,Frattarelli M,et al.131I radioconjugated antibodies for the locoregional radioimmunotherapy of high-grade malig-nant glioma:Phase I and II Study[J].Acta Oncologica,1999,38(3):351-359.
2 Riva P,Franceschi G,Riva N,et al.Role of nuclear medicine in the treatment of malignant gliomas:the locoregional radioimmunotherapy approach[J].Eur J Nucl Med,2000,27(5):601-609.
3 Santis RD,Anastasi AM,alessio VD.et al. Novel antitenascin antibody with increased tumour localisation for pretargeted antibodyguided radioimmunotherapy (PAGRITRR)[J].Br J Cancer,2003,88(07):996-1003.
4 Akabani G,Cokgor I,Coleman RE,et al.Dosimetry and dose-response relationships in newly diagnosed patients with malignant gliomas treated with iodine-131-labeled anti-tenascin monoclonal antibody 81C6 therapy[J].Int J Radia Oncol Biol Phys,2000,46(4):947-958.
5 Cokgor I,Akabani G,Kuan CT,et al.Phase I trial results of iodine-131 labeled antitenascin monoclonal antibody 81C6 treatment of patients with newly diagnosed malignant gliomas[J].J Clin Oncol,2000,18(22):3862-3872.
6 Goetz C,Rive P,Poepperl G,et al.Locoregional radioimmunotherapy in selected patients with malignant glioma:experience,side effects and survival times[J].J Neuro Oncol,2003,62:321-328.
7 Mahesparan R,Read TA,Lund-Johansen M,et al.Expression of extracellular matrix components in a highly infiltrative in vivo glioma model[J].Acta Neuropathologica,2003,105(1):49-57.
8 Akabani G,Reist CJ,Cokgor I,et al.Dosimetry of 131I-labeled 81C6 monoclonal antibody administered into surgically created resection cavities in patients with malignant brain tumors[J]. J Nucl Med,1999,40(4):631-638.
9 Hasegawa K,Yoshida T,Matsumoto K,et al.Differential expression of tenascin-C and tenascin-X in human astrocytomas[J].Acta Neu-ropathologica,1997,93:431-437.
10 Popperl G,Gotz C,Gildehaus FJ,et al.Initial experiences with adjuvant locoregional radioimmunotherapy using 131I-labeled monoclonal antibodies against tenascin(BC-4) for treatment of glioma (WHO IIIand TV)[J].Nuklearmedizin,2002,41(3):120-128.
11 Reardon DA,Akabani G,Edward CR,et al.Phase II trial of murine 131I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas[J].J Clin Oncol,2002,20(5):1389-1397.
12 Hopkins K,Chandler C,Eatough J,et al.Direct injection of 90Y-MoAbs into glioma tumor resection cavities leads to limited diffusion of the radioimmunoconjugates into normal brain parenchyma:a model to estimate absorbed radiation dose[J].Int J Radiat Oncol Biol Phys,1998,40(4):835-844.
13 Riva P,Franceschi G,Frattarelli M,et al.Loco-regional radioimmunotherapy of high-grade malignant gliomas using specific monoclonal antibodies labeled with 90Y:a Phase I study[J].Clin Cancer Res,1999,5:3275s-3280s.
14 Paganelli G,Grana C,Chinol M,et al.Antibody-guided three-step therapy for high grade glioma with yttrium-90 biotin[J].Eur J Nucl Med,1999,26(4):348-357.
15 Grana C,Chinol M,Robertson C.Pretargeted adjuvant radioimmunotherapy with yttrium-90-biotin in malignant glioma patients:a pilot study[J].Br J Cancer,2002,86:207-212.
16 Hauck ML,Larsen RH,Welsh PC,et al.Cytotoxicity of α-particle emitting astatine-211-labelled antibody in tumour spheroids:no effect of hyperthermia[J].Br J Cancer,1998,77(5):753-759.
17 Zalutsky MR,Zhao XG,Alston KL,et al.High-level production of α-particle emitting 211At and preparation of 211At labeled antibodies for clinical use[J].J Nucl Med,2001,42(10):1508-1515.
18 Imam SK.Advancement in cancer therapy with alpha-emitters:a review[J].Int J Radiat Oncol Biol Phys,2001,51(1):271-278.
相似文献/References:
[1]杨卫东,汪静.肿瘤核素靶向治疗新进展[J].国际放射医学核医学杂志,2015,39(1):19.[doi:10.3760/cma.j.issn.1673-4114.2015.01.006]
Yang Weidong,Wang Jing.Advance progress of radionuclide target tumor therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(4):19.[doi:10.3760/cma.j.issn.1673-4114.2015.01.006]
[2]田源,张良安.放射免疫治疗中的α核素微剂量研究[J].国际放射医学核医学杂志,2006,30(1):39.
TIAN Yuan,ZHANG Liang-an.A review of microdosimetric study in alpha particle radioimmunotherapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2006,30(4):39.
[3]薛景,刘芬菊.PI3K/Akt与胶质瘤辐射抗性[J].国际放射医学核医学杂志,2005,29(1):40.
XUE Jing,LIU Fen-ju.PI3K/Akt and radioresistance of glioma[J].International Journal of Radiation Medicine and Nuclear Medicine,2005,29(4):40.
[4]陈立波,朱瑞森.Bexxar治疗非霍奇金淋巴瘤的研究现状[J].国际放射医学核医学杂志,2005,29(2):67.
CHEN Li-bo,ZHU Rui-sen.Current status of Bexxar for treatment of non-Hodgkin’s lymphoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2005,29(4):67.
[5]刘影,李传福.功能性磁共振成像在胶质瘤中的应用[J].国际放射医学核医学杂志,2005,29(3):143.
LIU Ying,LI Chuan-fu.The value of functional MRI in glioma[J].International Journal of Radiation Medicine and Nuclear Medicine,2005,29(4):143.
[6]张弘.用于放免治疗的核素研究进展[J].国际放射医学核医学杂志,2003,27(4):148.
ZHANG Hong.Advances in radionuclide for radioimmunotherapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2003,27(4):148.
[7]李敏杰.胰腺癌的放射免疫治疗进展[J].国际放射医学核医学杂志,2003,27(4):154.
LI Min-jie.Radioimmunotherapy of pancreatic cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2003,27(4):154.
[8]袁志斌.ZevalinTM:一种放射免疫治疗新药[J].国际放射医学核医学杂志,2002,26(5):225.
YUAN Zhi-bin.ZevalinTM: A new radioimmunotherapy agent[J].International Journal of Radiation Medicine and Nuclear Medicine,2002,26(4):225.
[9]任均田,林学颜.放射免疫显像与治疗的应用进展[J].国际放射医学核医学杂志,1995,19(2):57.
[10]唐刚华,王世真.生物素-亲合素系统在核医学中的应用[J].国际放射医学核医学杂志,1997,21(4):145.